Harnessing nanoparticles for immunomodulation and vaccines
The first successful use of nanoparticles (NPs) for vaccination was reported almost 40 years ago with a virus-like particle-based vaccine against Hepatitis B. Since then, the term NP has been expanded to accommodate a large number of novel nano-sized particles engineered from a range of materials. T...
Κύριοι συγγραφείς: | Gomes, AC, Mohsen, M, Bachmann, M |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
MDPI
2017
|
Παρόμοια τεκμήρια
-
Harnessing nanoparticle technology for precision medicine in head and neck cancer: Targeted delivery, immunomodulation, and clinical translation
ανά: Karthikeyan Elumalai, κ.ά.
Έκδοση: (2025-12-01) -
Harnessing immunomodulation to combat sarcopenia: current insights and possible approaches
ανά: Ning Zhang, κ.ά.
Έκδοση: (2024-08-01) -
Harnessing the potential of the NALT and BALT as targets for immunomodulation using engineering strategies to enhance mucosal uptake
ανά: Madison L. Seefeld, κ.ά.
Έκδοση: (2024-09-01) -
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
ανά: Jeffrey Schlom, κ.ά.
Έκδοση: (2020-05-01) -
Harnessing endoscopic ultrasound-guided radiofrequency ablation to reshape the pancreatic ductal adenocarcinoma microenvironment and elicit systemic immunomodulation
ανά: Vishali Moond, κ.ά.
Έκδοση: (2024-08-01)